At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Dasatinib +1 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
In Brief
A Phase 2 clinical trial evaluating Dasatinib and Fulvestrant for Advanced Breast Cancer. Completed, enrolled 100 participants across 28 sites.
Detailed Summary
The purpose of this study is to find out what effect the combination of fulvestrant (Faslodex) and dasatinib (Sprycel) has on advanced breast cancer compared to fulvestrant alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionNov 2011
Study CompletionJan 2014
TodayJul 2026
First PostedSep 17, 2008
Enrollment StartSep 1, 2008
Primary CompletionNov 1, 2011
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.8 years ago
Interventions
Dasatinibdrug
Tablets, Oral, 100 mg, once daily (QD), upto 2 years
Fulvestrantdrug
Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years